David Church
Concepts (340)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Muscle, Skeletal | 29 | 2026 | 815 | 5.210 |
Why?
| | Muscle Proteins | 14 | 2026 | 350 | 3.370 |
Why?
| | Exercise | 24 | 2026 | 561 | 2.570 |
Why?
| | Resistance Training | 16 | 2025 | 106 | 2.080 |
Why?
| | Dietary Supplements | 16 | 2025 | 479 | 1.950 |
Why?
| | Dietary Proteins | 9 | 2024 | 255 | 1.780 |
Why?
| | Insulin Antibodies | 3 | 2021 | 4 | 1.780 |
Why?
| | Autoimmune Diseases | 3 | 2021 | 90 | 1.650 |
Why?
| | Aging | 6 | 2025 | 714 | 1.570 |
Why?
| | Sarcopenia | 5 | 2025 | 100 | 1.520 |
Why?
| | Insulin | 10 | 2025 | 493 | 1.490 |
Why?
| | Amino Acids, Essential | 7 | 2026 | 141 | 1.400 |
Why?
| | Cat Diseases | 5 | 2025 | 9 | 1.090 |
Why?
| | Amino Acids | 5 | 2023 | 382 | 1.040 |
Why?
| | Military Personnel | 5 | 2022 | 173 | 1.000 |
Why?
| | Protein Biosynthesis | 6 | 2026 | 268 | 0.960 |
Why?
| | Carnosine | 4 | 2018 | 5 | 0.950 |
Why?
| | Meals | 3 | 2024 | 65 | 0.920 |
Why?
| | Athletic Performance | 4 | 2020 | 32 | 0.870 |
Why?
| | Diet | 8 | 2024 | 610 | 0.860 |
Why?
| | beta-Alanine | 3 | 2018 | 10 | 0.820 |
Why?
| | Young Adult | 32 | 2026 | 4511 | 0.790 |
Why?
| | Feeding Behavior | 1 | 2024 | 195 | 0.770 |
Why?
| | Male | 52 | 2026 | 27435 | 0.770 |
Why?
| | Humans | 73 | 2026 | 53230 | 0.770 |
Why?
| | Congenital Hyperinsulinism | 2 | 2018 | 4 | 0.710 |
Why?
| | Muscle Contraction | 2 | 2019 | 114 | 0.700 |
Why?
| | Enteral Nutrition | 4 | 2026 | 157 | 0.690 |
Why?
| | Hyperinsulinism | 1 | 2021 | 30 | 0.690 |
Why?
| | Hypoglycemia | 1 | 2021 | 62 | 0.660 |
Why?
| | Chromatography, Gel | 2 | 2018 | 38 | 0.650 |
Why?
| | Anabolic Agents | 3 | 2025 | 41 | 0.650 |
Why?
| | Mice, Inbred C57BL | 3 | 2025 | 1925 | 0.640 |
Why?
| | Peptides | 1 | 2021 | 234 | 0.630 |
Why?
| | Insulin-Like Growth Factor I | 3 | 2016 | 141 | 0.620 |
Why?
| | Caloric Restriction | 3 | 2025 | 39 | 0.610 |
Why?
| | Muscle Strength | 5 | 2025 | 132 | 0.610 |
Why?
| | Adult | 33 | 2026 | 14534 | 0.610 |
Why?
| | Military Medicine | 1 | 2019 | 24 | 0.600 |
Why?
| | Stress, Physiological | 2 | 2019 | 184 | 0.580 |
Why?
| | Muscular Atrophy | 1 | 2019 | 73 | 0.580 |
Why?
| | Liver | 2 | 2024 | 1150 | 0.580 |
Why?
| | Occupational Diseases | 1 | 2019 | 82 | 0.570 |
Why?
| | Leucine | 3 | 2023 | 114 | 0.560 |
Why?
| | Brain-Derived Neurotrophic Factor | 2 | 2025 | 30 | 0.540 |
Why?
| | Parenteral Nutrition | 3 | 2026 | 29 | 0.530 |
Why?
| | Arthroplasty, Replacement, Hip | 1 | 2021 | 268 | 0.530 |
Why?
| | Cross-Over Studies | 10 | 2022 | 241 | 0.520 |
Why?
| | Polyphenols | 4 | 2018 | 40 | 0.520 |
Why?
| | Double-Blind Method | 11 | 2026 | 729 | 0.510 |
Why?
| | Chemical Precipitation | 1 | 2016 | 4 | 0.510 |
Why?
| | TOR Serine-Threonine Kinases | 2 | 2016 | 83 | 0.510 |
Why?
| | Dermatitis, Allergic Contact | 1 | 2016 | 12 | 0.510 |
Why?
| | Immunoassay | 1 | 2016 | 23 | 0.500 |
Why?
| | Triterpenes | 1 | 2016 | 11 | 0.490 |
Why?
| | Colorectal Neoplasms | 4 | 2024 | 302 | 0.490 |
Why?
| | Multiprotein Complexes | 1 | 2016 | 25 | 0.490 |
Why?
| | Blood Glucose Self-Monitoring | 1 | 2016 | 47 | 0.490 |
Why?
| | Female | 29 | 2026 | 28782 | 0.480 |
Why?
| | Fatigue | 3 | 2025 | 127 | 0.470 |
Why?
| | Coffee | 1 | 2015 | 11 | 0.460 |
Why?
| | Neoplasm Proteins | 2 | 2016 | 330 | 0.460 |
Why?
| | Endometrial Neoplasms | 3 | 2024 | 143 | 0.460 |
Why?
| | Reaction Time | 1 | 2015 | 207 | 0.440 |
Why?
| | Nandrolone | 2 | 2025 | 5 | 0.440 |
Why?
| | Polymorphism, Genetic | 2 | 2014 | 181 | 0.430 |
Why?
| | Monocytes | 4 | 2018 | 126 | 0.410 |
Why?
| | Malnutrition | 2 | 2026 | 95 | 0.400 |
Why?
| | Dietary Carbohydrates | 3 | 2026 | 91 | 0.400 |
Why?
| | Neoplasms | 3 | 2026 | 1334 | 0.390 |
Why?
| | Aged | 12 | 2025 | 10429 | 0.390 |
Why?
| | Animals | 14 | 2025 | 13526 | 0.390 |
Why?
| | Muscle Fatigue | 3 | 2025 | 15 | 0.390 |
Why?
| | Quadriceps Muscle | 3 | 2018 | 47 | 0.390 |
Why?
| | Diabetes Mellitus, Type 2 | 2 | 2016 | 591 | 0.390 |
Why?
| | Phenylalanine | 3 | 2022 | 136 | 0.370 |
Why?
| | Postprandial Period | 3 | 2021 | 75 | 0.370 |
Why?
| | Signal Transduction | 6 | 2026 | 1748 | 0.360 |
Why?
| | Valerates | 3 | 2017 | 39 | 0.360 |
Why?
| | Diabetes Mellitus | 3 | 2025 | 321 | 0.360 |
Why?
| | Energy Metabolism | 3 | 2026 | 324 | 0.360 |
Why?
| | Infant, Premature | 2 | 2024 | 331 | 0.330 |
Why?
| | C-Peptide | 2 | 2021 | 25 | 0.320 |
Why?
| | Middle Aged | 11 | 2025 | 13419 | 0.320 |
Why?
| | Blood Glucose | 3 | 2018 | 490 | 0.310 |
Why?
| | Neoadjuvant Therapy | 2 | 2024 | 124 | 0.310 |
Why?
| | Tumor Necrosis Factor-alpha | 4 | 2025 | 392 | 0.310 |
Why?
| | Antineoplastic Agents | 2 | 2016 | 1232 | 0.300 |
Why?
| | Cytokines | 3 | 2017 | 627 | 0.300 |
Why?
| | Receptors, Tumor Necrosis Factor, Type I | 3 | 2017 | 38 | 0.300 |
Why?
| | Polyethylene Glycols | 2 | 2021 | 95 | 0.290 |
Why?
| | Proteins | 2 | 2022 | 351 | 0.290 |
Why?
| | Paresthesia | 2 | 2018 | 8 | 0.280 |
Why?
| | Physical Conditioning, Animal | 2 | 2025 | 67 | 0.280 |
Why?
| | Cats | 5 | 2025 | 75 | 0.270 |
Why?
| | Histidine | 2 | 2017 | 15 | 0.270 |
Why?
| | Quality of Life | 2 | 2025 | 902 | 0.270 |
Why?
| | Eating | 4 | 2022 | 159 | 0.260 |
Why?
| | Meat | 2 | 2024 | 60 | 0.260 |
Why?
| | Exercise Test | 5 | 2019 | 137 | 0.250 |
Why?
| | Gastric Balloon | 1 | 2026 | 3 | 0.240 |
Why?
| | Nutritional Status | 3 | 2026 | 148 | 0.240 |
Why?
| | Intubation, Gastrointestinal | 1 | 2026 | 25 | 0.240 |
Why?
| | Adolescent | 10 | 2024 | 6907 | 0.240 |
Why?
| | Gastrostomy | 1 | 2026 | 56 | 0.230 |
Why?
| | Nerve Growth Factors | 1 | 2025 | 26 | 0.230 |
Why?
| | Nicotinamide Mononucleotide | 1 | 2025 | 4 | 0.230 |
Why?
| | Cancer Vaccines | 1 | 2026 | 79 | 0.230 |
Why?
| | Isometric Contraction | 4 | 2018 | 20 | 0.230 |
Why?
| | Niacinamide | 1 | 2025 | 24 | 0.230 |
Why?
| | Diet, Reducing | 1 | 2025 | 39 | 0.230 |
Why?
| | Sirolimus | 1 | 2025 | 72 | 0.220 |
Why?
| | Dopamine | 1 | 2025 | 167 | 0.220 |
Why?
| | DNA Mismatch Repair | 1 | 2024 | 18 | 0.220 |
Why?
| | Serotonin | 1 | 2025 | 144 | 0.220 |
Why?
| | Athletes | 3 | 2020 | 104 | 0.210 |
Why?
| | Metformin | 1 | 2025 | 84 | 0.210 |
Why?
| | Cattle | 1 | 2024 | 207 | 0.210 |
Why?
| | Digestion | 2 | 2020 | 29 | 0.200 |
Why?
| | Hippocampus | 1 | 2025 | 195 | 0.200 |
Why?
| | Androgens | 1 | 2024 | 70 | 0.200 |
Why?
| | Adipose Tissue | 1 | 2025 | 210 | 0.200 |
Why?
| | Random Allocation | 1 | 2024 | 284 | 0.200 |
Why?
| | Enterocolitis, Necrotizing | 1 | 2023 | 39 | 0.200 |
Why?
| | Proteolysis | 2 | 2020 | 105 | 0.200 |
Why?
| | Head and Neck Neoplasms | 1 | 2026 | 291 | 0.190 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2024 | 238 | 0.190 |
Why?
| | Nutrition Assessment | 2 | 2026 | 67 | 0.190 |
Why?
| | Chemokine CCL2 | 3 | 2018 | 66 | 0.190 |
Why?
| | Hypoglycemic Agents | 3 | 2025 | 227 | 0.180 |
Why?
| | Colonic Neoplasms | 1 | 2023 | 162 | 0.180 |
Why?
| | Mice | 4 | 2025 | 5982 | 0.180 |
Why?
| | MicroRNAs | 1 | 2026 | 397 | 0.180 |
Why?
| | Risk Factors | 4 | 2019 | 4017 | 0.180 |
Why?
| | Body Mass Index | 4 | 2021 | 717 | 0.180 |
Why?
| | Proinsulin | 1 | 2021 | 1 | 0.180 |
Why?
| | Molecular Weight | 1 | 2021 | 77 | 0.170 |
Why?
| | Dogs | 2 | 2019 | 186 | 0.170 |
Why?
| | Food Analysis | 1 | 2021 | 27 | 0.170 |
Why?
| | Infusions, Intravenous | 1 | 2021 | 211 | 0.170 |
Why?
| | Metabolism | 1 | 2020 | 25 | 0.170 |
Why?
| | Myocardium | 1 | 2024 | 471 | 0.170 |
Why?
| | Actinidia | 1 | 2020 | 8 | 0.170 |
Why?
| | Food | 1 | 2020 | 69 | 0.160 |
Why?
| | Running | 2 | 2020 | 23 | 0.160 |
Why?
| | Chromatography, Liquid | 1 | 2021 | 245 | 0.160 |
Why?
| | Polymorphism, Single Nucleotide | 2 | 2020 | 505 | 0.160 |
Why?
| | Epigenomics | 1 | 2020 | 76 | 0.160 |
Why?
| | Carbohydrate Metabolism | 1 | 2019 | 25 | 0.160 |
Why?
| | Tandem Mass Spectrometry | 1 | 2021 | 254 | 0.150 |
Why?
| | Receptors, CCR2 | 2 | 2016 | 13 | 0.150 |
Why?
| | Insulin Resistance | 2 | 2018 | 282 | 0.150 |
Why?
| | Physical Fitness | 2 | 2016 | 56 | 0.150 |
Why?
| | Adaptation, Physiological | 1 | 2020 | 109 | 0.150 |
Why?
| | Kinetics | 1 | 2020 | 607 | 0.150 |
Why?
| | Testosterone | 4 | 2023 | 142 | 0.150 |
Why?
| | Hormones | 1 | 2019 | 58 | 0.150 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 2 | 2016 | 1043 | 0.150 |
Why?
| | Kidney | 1 | 2024 | 715 | 0.150 |
Why?
| | Prednisolone | 1 | 2019 | 56 | 0.150 |
Why?
| | Occupational Health | 1 | 2019 | 64 | 0.150 |
Why?
| | Proteome | 1 | 2020 | 177 | 0.150 |
Why?
| | Patient Compliance | 2 | 2017 | 232 | 0.150 |
Why?
| | Alzheimer Disease | 1 | 2023 | 338 | 0.150 |
Why?
| | Diazoxide | 1 | 2018 | 7 | 0.150 |
Why?
| | Football | 2 | 2016 | 75 | 0.140 |
Why?
| | Lactic Acid | 2 | 2016 | 78 | 0.140 |
Why?
| | Delayed-Action Preparations | 1 | 2018 | 58 | 0.140 |
Why?
| | Drug Prescriptions | 1 | 2019 | 116 | 0.140 |
Why?
| | Martial Arts | 1 | 2017 | 1 | 0.140 |
Why?
| | Receptors, Tumor Necrosis Factor, Type II | 1 | 2017 | 15 | 0.140 |
Why?
| | Societies, Medical | 3 | 2026 | 207 | 0.140 |
Why?
| | Syndrome | 1 | 2018 | 248 | 0.140 |
Why?
| | Cognition | 2 | 2023 | 346 | 0.130 |
Why?
| | Hand Strength | 1 | 2017 | 25 | 0.130 |
Why?
| | Glucose | 1 | 2019 | 361 | 0.130 |
Why?
| | Accidents, Traffic | 1 | 2018 | 91 | 0.130 |
Why?
| | Insulin, Lente | 1 | 2017 | 1 | 0.130 |
Why?
| | Insulin, Isophane | 1 | 2017 | 3 | 0.130 |
Why?
| | Glucocorticoids | 1 | 2019 | 236 | 0.130 |
Why?
| | Postural Balance | 1 | 2017 | 59 | 0.130 |
Why?
| | Supine Position | 1 | 2016 | 26 | 0.130 |
Why?
| | Physical Education and Training | 1 | 2016 | 23 | 0.130 |
Why?
| | Granulocytes | 1 | 2016 | 27 | 0.130 |
Why?
| | Work Capacity Evaluation | 1 | 2016 | 21 | 0.130 |
Why?
| | Energy Intake | 3 | 2024 | 186 | 0.130 |
Why?
| | Dietary Fats | 1 | 2017 | 133 | 0.130 |
Why?
| | Insulin-Like Growth Factor Binding Proteins | 1 | 2016 | 27 | 0.130 |
Why?
| | Milk Proteins | 1 | 2017 | 77 | 0.130 |
Why?
| | Patient Positioning | 1 | 2016 | 31 | 0.130 |
Why?
| | Methylprednisolone | 1 | 2016 | 41 | 0.130 |
Why?
| | Immunosuppressive Agents | 1 | 2018 | 253 | 0.120 |
Why?
| | Antioxidants | 1 | 2018 | 264 | 0.120 |
Why?
| | Antimetabolites, Antineoplastic | 1 | 2016 | 39 | 0.120 |
Why?
| | Mitogen-Activated Protein Kinase Kinases | 1 | 2016 | 34 | 0.120 |
Why?
| | Hydrocortisone | 4 | 2017 | 113 | 0.120 |
Why?
| | Rest | 1 | 2016 | 60 | 0.120 |
Why?
| | Performance-Enhancing Substances | 1 | 2015 | 5 | 0.120 |
Why?
| | Clonal Evolution | 1 | 2016 | 59 | 0.120 |
Why?
| | MAP Kinase Signaling System | 1 | 2016 | 127 | 0.120 |
Why?
| | DNA, Neoplasm | 1 | 2016 | 146 | 0.120 |
Why?
| | Plant Extracts | 1 | 2018 | 200 | 0.110 |
Why?
| | Genome-Wide Association Study | 1 | 2016 | 184 | 0.110 |
Why?
| | Caffeine | 1 | 2015 | 64 | 0.110 |
Why?
| | Mutation | 2 | 2018 | 1337 | 0.110 |
Why?
| | Ultrasonography | 1 | 2016 | 426 | 0.110 |
Why?
| | NF-kappa B | 1 | 2016 | 327 | 0.110 |
Why?
| | Esophageal Neoplasms | 1 | 2016 | 113 | 0.110 |
Why?
| | Body Composition | 3 | 2022 | 355 | 0.110 |
Why?
| | Dihydrouracil Dehydrogenase (NADP) | 1 | 2014 | 1 | 0.110 |
Why?
| | Postoperative Complications | 1 | 2021 | 1099 | 0.110 |
Why?
| | Thymidylate Synthase | 1 | 2014 | 10 | 0.110 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2017 | 1367 | 0.110 |
Why?
| | Deoxycytidine | 1 | 2014 | 26 | 0.100 |
Why?
| | Heart Rate | 1 | 2015 | 314 | 0.100 |
Why?
| | Fluorouracil | 1 | 2014 | 59 | 0.100 |
Why?
| | Blood Pressure | 1 | 2015 | 518 | 0.100 |
Why?
| | Genetic Predisposition to Disease | 1 | 2016 | 533 | 0.100 |
Why?
| | United States | 4 | 2026 | 5409 | 0.090 |
Why?
| | Time Factors | 4 | 2021 | 2991 | 0.090 |
Why?
| | Myoglobin | 3 | 2017 | 25 | 0.090 |
Why?
| | Adenocarcinoma | 1 | 2016 | 405 | 0.090 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2016 | 647 | 0.090 |
Why?
| | Practice Guidelines as Topic | 1 | 2015 | 502 | 0.090 |
Why?
| | Infant | 3 | 2026 | 3805 | 0.090 |
Why?
| | Tyrosine | 2 | 2022 | 92 | 0.090 |
Why?
| | Treatment Outcome | 2 | 2024 | 5595 | 0.090 |
Why?
| | Oxygen Consumption | 2 | 2020 | 201 | 0.070 |
Why?
| | Macrophage-1 Antigen | 2 | 2018 | 6 | 0.070 |
Why?
| | Chemokine CX3CL1 | 2 | 2018 | 8 | 0.070 |
Why?
| | Creatine Kinase | 2 | 2017 | 31 | 0.060 |
Why?
| | L-Lactate Dehydrogenase | 2 | 2017 | 57 | 0.060 |
Why?
| | Leg | 2 | 2017 | 123 | 0.060 |
Why?
| | Promoter Regions, Genetic | 2 | 2020 | 465 | 0.060 |
Why?
| | Infant, Newborn | 2 | 2024 | 2913 | 0.060 |
Why?
| | Drug Administration Schedule | 2 | 2018 | 370 | 0.060 |
Why?
| | Veterinary Medicine | 1 | 2025 | 8 | 0.060 |
Why?
| | Child, Preschool | 2 | 2026 | 4162 | 0.060 |
Why?
| | Diffusion Tensor Imaging | 2 | 2017 | 104 | 0.060 |
Why?
| | Receptor, Serotonin, 5-HT1A | 1 | 2025 | 6 | 0.060 |
Why?
| | Receptor, trkB | 1 | 2025 | 8 | 0.060 |
Why?
| | Nutritional Requirements | 1 | 2026 | 70 | 0.060 |
Why?
| | Pyridinium Compounds | 1 | 2025 | 20 | 0.060 |
Why?
| | Antigens, Neoplasm | 1 | 2026 | 146 | 0.060 |
Why?
| | Child | 3 | 2026 | 7379 | 0.060 |
Why?
| | Consensus | 1 | 2025 | 206 | 0.050 |
Why?
| | Behavior, Animal | 1 | 2025 | 187 | 0.050 |
Why?
| | Keratins | 1 | 2024 | 27 | 0.050 |
Why?
| | Immunotherapy | 1 | 2026 | 266 | 0.050 |
Why?
| | STAT3 Transcription Factor | 1 | 2024 | 89 | 0.050 |
Why?
| | Neoplastic Syndromes, Hereditary | 1 | 2023 | 18 | 0.050 |
Why?
| | Crime | 1 | 2023 | 28 | 0.050 |
Why?
| | Micronutrients | 1 | 2023 | 18 | 0.050 |
Why?
| | Phylogeny | 1 | 2023 | 231 | 0.050 |
Why?
| | Predictive Value of Tests | 2 | 2016 | 934 | 0.050 |
Why?
| | Polyesters | 1 | 2022 | 14 | 0.050 |
Why?
| | Nutrition Surveys | 1 | 2023 | 118 | 0.050 |
Why?
| | Memory, Short-Term | 1 | 2023 | 74 | 0.050 |
Why?
| | Residence Characteristics | 1 | 2023 | 163 | 0.050 |
Why?
| | Isotopes | 1 | 2022 | 26 | 0.050 |
Why?
| | Cross-Sectional Studies | 2 | 2018 | 1723 | 0.040 |
Why?
| | Tumor Microenvironment | 1 | 2023 | 274 | 0.040 |
Why?
| | Egg Proteins | 1 | 2021 | 18 | 0.040 |
Why?
| | Food, Fortified | 1 | 2021 | 27 | 0.040 |
Why?
| | Basal Metabolism | 1 | 2020 | 32 | 0.040 |
Why?
| | Plant Proteins | 1 | 2021 | 72 | 0.040 |
Why?
| | Microsatellite Instability | 1 | 2020 | 21 | 0.040 |
Why?
| | Oxidative Stress | 1 | 2025 | 819 | 0.040 |
Why?
| | Meta-Analysis as Topic | 1 | 2020 | 40 | 0.040 |
Why?
| | Anaerobiosis | 1 | 2020 | 21 | 0.040 |
Why?
| | Disease Models, Animal | 1 | 2025 | 1517 | 0.040 |
Why?
| | Growth Differentiation Factors | 1 | 2020 | 2 | 0.040 |
Why?
| | Follistatin | 1 | 2020 | 2 | 0.040 |
Why?
| | Myostatin | 1 | 2020 | 10 | 0.040 |
Why?
| | Gene Silencing | 1 | 2020 | 122 | 0.040 |
Why?
| | Puberty | 1 | 2020 | 28 | 0.040 |
Why?
| | Metabolic Clearance Rate | 1 | 2019 | 66 | 0.040 |
Why?
| | Cell Line, Tumor | 1 | 2024 | 1470 | 0.040 |
Why?
| | Brain Neoplasms | 1 | 2023 | 319 | 0.040 |
Why?
| | Fruit | 1 | 2020 | 129 | 0.040 |
Why?
| | Alleles | 1 | 2020 | 277 | 0.040 |
Why?
| | Bone Morphogenetic Proteins | 1 | 2020 | 67 | 0.040 |
Why?
| | Retrospective Studies | 2 | 2024 | 6819 | 0.040 |
Why?
| | Cohort Studies | 1 | 2023 | 1557 | 0.040 |
Why?
| | Acute Disease | 1 | 2019 | 393 | 0.040 |
Why?
| | Oxidation-Reduction | 1 | 2019 | 333 | 0.040 |
Why?
| | Sex Factors | 1 | 2020 | 747 | 0.030 |
Why?
| | DNA Mutational Analysis | 1 | 2018 | 179 | 0.030 |
Why?
| | Solubility | 1 | 2017 | 83 | 0.030 |
Why?
| | Sus scrofa | 1 | 2017 | 38 | 0.030 |
Why?
| | Probiotics | 1 | 2017 | 25 | 0.030 |
Why?
| | Fluid Shifts | 1 | 2016 | 3 | 0.030 |
Why?
| | Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2016 | 51 | 0.030 |
Why?
| | RNA, Messenger | 1 | 2020 | 1133 | 0.030 |
Why?
| | Interleukin-8 | 1 | 2016 | 85 | 0.030 |
Why?
| | Chromosomes, Human, Pair 8 | 1 | 2016 | 15 | 0.030 |
Why?
| | Ribonucleoprotein, U2 Small Nuclear | 1 | 2016 | 1 | 0.030 |
Why?
| | TATA-Binding Protein Associated Factors | 1 | 2016 | 2 | 0.030 |
Why?
| | Transcription Factor TFIID | 1 | 2016 | 5 | 0.030 |
Why?
| | Cyclin D2 | 1 | 2016 | 21 | 0.030 |
Why?
| | Physical Exertion | 1 | 2016 | 45 | 0.030 |
Why?
| | Electromyography | 1 | 2016 | 128 | 0.030 |
Why?
| | Anthropometry | 1 | 2016 | 101 | 0.030 |
Why?
| | C-Reactive Protein | 1 | 2017 | 152 | 0.030 |
Why?
| | Recovery of Function | 1 | 2017 | 203 | 0.030 |
Why?
| | Genetic Heterogeneity | 1 | 2016 | 20 | 0.030 |
Why?
| | Physical Examination | 1 | 2016 | 96 | 0.030 |
Why?
| | Exome | 1 | 2016 | 54 | 0.030 |
Why?
| | Histone Acetyltransferases | 1 | 2016 | 26 | 0.030 |
Why?
| | DNA Methylation | 1 | 2020 | 592 | 0.030 |
Why?
| | Biopsy | 1 | 2018 | 600 | 0.030 |
Why?
| | Physical Endurance | 1 | 2016 | 35 | 0.030 |
Why?
| | Drug Therapy, Combination | 1 | 2017 | 405 | 0.030 |
Why?
| | Interleukin-6 | 1 | 2017 | 272 | 0.030 |
Why?
| | DNA Copy Number Variations | 1 | 2016 | 117 | 0.030 |
Why?
| | Analysis of Variance | 1 | 2016 | 547 | 0.030 |
Why?
| | Risk Assessment | 1 | 2020 | 1368 | 0.030 |
Why?
| | Universities | 1 | 2016 | 186 | 0.030 |
Why?
| | Phosphoproteins | 1 | 2016 | 117 | 0.030 |
Why?
| | Human Growth Hormone | 1 | 2015 | 49 | 0.030 |
Why?
| | Immunity, Innate | 1 | 2016 | 112 | 0.030 |
Why?
| | Immunohistochemistry | 1 | 2018 | 975 | 0.030 |
Why?
| | Insulin, Long-Acting | 1 | 2015 | 2 | 0.030 |
Why?
| | Sequence Analysis, DNA | 1 | 2016 | 216 | 0.030 |
Why?
| | International Agencies | 1 | 2015 | 16 | 0.030 |
Why?
| | Primary Health Care | 1 | 2019 | 404 | 0.030 |
Why?
| | Administration, Oral | 1 | 2016 | 456 | 0.030 |
Why?
| | Prevalence | 1 | 2018 | 1034 | 0.030 |
Why?
| | Sample Size | 1 | 2014 | 50 | 0.030 |
Why?
| | Body Weight | 1 | 2016 | 524 | 0.030 |
Why?
| | Remission Induction | 1 | 2014 | 221 | 0.030 |
Why?
| | Genetic Markers | 1 | 2014 | 104 | 0.030 |
Why?
| | Cells, Cultured | 1 | 2017 | 1569 | 0.030 |
Why?
| | Reproducibility of Results | 1 | 2016 | 1219 | 0.020 |
Why?
| | Inflammation | 1 | 2017 | 652 | 0.020 |
Why?
| | Apoptosis | 1 | 2018 | 1139 | 0.020 |
Why?
| | Research Design | 1 | 2014 | 373 | 0.020 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2016 | 868 | 0.020 |
Why?
| | Prospective Studies | 1 | 2017 | 2411 | 0.020 |
Why?
| | Magnetic Resonance Imaging | 1 | 2016 | 1583 | 0.020 |
Why?
|
|
Church's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|